TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19124650

Group type: EXPERIMENTAL
Intervention: Print referencing style during storybook reading sessions (120 sessions over 30 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Normal reading style (comparison group)
Number of subjects: 106
Study: 15716561

Group type: EXPERIMENTAL
Intervention: Expedited treatment of sexual partners
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Standard partner referral
Number of subjects: 1860

Group type: EXPERIMENTAL
Intervention: Expedited treatment of sexual partners (gonorrhea)
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Standard partner referral (gonorrhea)
Number of subjects: 1860

Group type: EXPERIMENTAL
Intervention: Expedited treatment of sexual partners (chlamydial infection)
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Standard partner referral (chlamydial infection)
Number of subjects: 1860
Study: 12881083

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 100 micrograms every 4 hours (max 500 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone 6 mg every 6 hours (max 24 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal glyceryl trinitrate 500 micrograms every 6 hours (max 2.5 mg)
Number of subjects: 0
Study: 10437864

Group type: EXPERIMENTAL
Intervention: Immunisation with paternal mononuclear cells (treatment)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 183
Study: 8848700

Group type: EXPERIMENTAL
Intervention: 5-HT2-receptor antagonist ketanserine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2229452

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 19
Study: 358757

Group type: EXPERIMENTAL
Intervention: Amipaque 260
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isopaque 260
Number of subjects: 0
Study: 29611536

Group type: EXPERIMENTAL
Intervention: Medium medical ozone (40 μg/ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low medical ozone (20 μg/ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High medical ozone (60 μg/ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 27829455

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (ordinary case management)
Number of subjects: 443
Study: 23911196

Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg weekly (Taspo10)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg weekly (Taspo20)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Exenatide 10 mcg BID (Exe)
Number of subjects: 148
Study: 22726466

Group type: EXPERIMENTAL
Intervention: New stent
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional stent
Number of subjects: 80
Study: 19679600

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 19172548

Group type: EXPERIMENTAL
Intervention: Nasal testosterone 7.6mg, 15.2mg, or 22.8mg (single dose)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nasal testosterone 7.6mg (twice or three times a day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nasal testosterone (all doses)
Number of subjects: 29
Study: 16275194

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12161829

Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation of the quadriceps muscle
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo stimulation of the quadriceps muscle
Number of subjects: 24
Study: 9951570

Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Synthetic adrenocorticotropic hormone (ACTH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7811163

Group type: EXPERIMENTAL
Intervention: DISC‐PC (combined algorithm)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: DISC‐P (parent information only)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: DISC‐C (child information only)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Community sample
Number of subjects: 375
Study: 2190461

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray 1.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray 5.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 378754

Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg daily, 5 days a week
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 43
Study: 30950691

Group type: COMPARATOR
Intervention: native‐accented (Midland American English) speech
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: nonnative‐accented (Spanish‐ and Japanese‐accented English) speech
Number of subjects: 120
Study: 29135865

Group type: EXPERIMENTAL
Intervention: Methylprednisolone administered intravenously before cochlear implantation
Number of subjects: 74

Group type: COMPARATOR
Intervention: No steroid administration (control group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Patients exhibiting spikes
Number of subjects: 74

Group type: COMPARATOR
Intervention: Steroid administration
Number of subjects: 74
Study: 25371029

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham laser (control)
Number of subjects: 60
Study: 24368465

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 61
Study: 21767798

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Moderate to severe depression treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Training and benchmark information
Number of subjects: 14
Study: 19209097

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (2 doses at 2 and 4 months of age)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (booster dose at 12 months)
Number of subjects: 180
Study: 16721464

Group type: COMPARATOR
Intervention: Control (no debonding/rebonding)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recycled brackets (aluminum oxide blasting)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recycled brackets (new brackets attached to previously bonded teeth)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recycled brackets (specialized company)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recycled brackets (silicon carbide stone grinding)
Number of subjects: 50
Study: 12642956

Group type: EXPERIMENTAL
Intervention: Fixed prostheses on implants (upper jaw)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Removable prostheses on implants
Number of subjects: 164

Group type: COMPARATOR
Intervention: Natural dentition (control group)
Number of subjects: 164
Study: 10721826

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using topically applied delta‐aminolevulinic acid
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Laser-Doppler perfusion imaging technique
Number of subjects: 526

Group type: COMPARATOR
Intervention: Recurrent lesions
Number of subjects: 526
Study: 8958856

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Paracetamol (PAR)
Number of subjects: 473
Study: 1404352

Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Perceived seriousness of hypercholesterolemia
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Expectation of benefit from treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Depressed feelings of helplessness and hopelessness
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Perception of health status being under the control of chance or powerful others
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 31
Study: 3893185

Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal polysaccharide vaccine
Number of subjects: 3340

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 3340
Study: 31533777

Group type: EXPERIMENTAL
Intervention: Letrozole (LTZ) 2.5 mg/day for 3 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oral metronomic vinorelbine (mVNB) 50 mg 3 days/week for 3 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of LTZ and mVNB
Number of subjects: 61

Group type: COMPARATOR
Intervention: LTZ
Number of subjects: 61

Group type: COMPARATOR
Intervention: LTZ+mVNB
Number of subjects: 61
Study: 29270828

Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1012
Study: 27539586

Group type: EXPERIMENTAL
Intervention: BEAT Cancer
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 222
Study: 25323062

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Anxiety Management (AM)
Number of subjects: 46
Study: 22502772

Group type: EXPERIMENTAL
Intervention: Entropy group (visible entropy values)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (invisible entropy values)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 19969339

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol combination therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Budesonide alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18947348

Group type: EXPERIMENTAL
Intervention: Younger adults; mood-congruent gaze
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults; mood-incongruent positive gaze
Number of subjects: 0
Study: 15965894

Group type: EXPERIMENTAL
Intervention: Albuterol 2.5 mg nebulized
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo nebulized
Number of subjects: 19
Study: 14727987

Group type: EXPERIMENTAL
Intervention: Trimetazidine 20 mg, 3 times daily for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10660274

Group type: EXPERIMENTAL
Intervention: Bath at 1 hour of age
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bath at 2 hours of age
Number of subjects: 80
Study: 9007781

Group type: EXPERIMENTAL
Intervention: Fibre-optic phototherapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Conventional daylight phototherapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination of both phototherapy types
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (unexposed infants)
Number of subjects: 123
Study: 1381690

Group type: EXPERIMENTAL
Intervention: lignocaine‐dextran
Number of subjects: 20

Group type: COMPARATOR
Intervention: lignocaine‐saline
Number of subjects: 20
Study: 6388516

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 25 ng/kg/min during CPB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo during CPB
Number of subjects: 50
Study: 29365333

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28601610

Group type: EXPERIMENTAL
Intervention: OAC (omeprazole, amoxicillin, clarithromycin)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: OTMB (omeprazole, tetracycline, metronidazole, bismuth)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: OACB (omeprazole, amoxicillin, clarithromycin, bismuth)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: OA+OCM (omeprazole, amoxicillin, metronidazole)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: OA+OCMB (omeprazole, amoxicillin, metronidazole, bismuth)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: OA+OMDB (omeprazole, amoxicillin, metronidazole, doxycycline, bismuth)
Number of subjects: 301
Study: 26385671

Group type: EXPERIMENTAL
Intervention: Pain treatment protocol and education program
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 156
Study: 22035345

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PMMA IOL
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IOL dioptric power (Hydrophobic acrylic IOL)
Number of subjects: 46
Study: 20880055

Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg b.i.d. for 3 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19463308

Group type: EXPERIMENTAL
Intervention: Interceptor PLUS Coronary Filter System
Number of subjects: 797

Group type: COMPARATOR
Intervention: Control distal-protection devices (GuardWire, FilterWire EZ)
Number of subjects: 797
Study: 16927868

Group type: EXPERIMENTAL
Intervention: Conservative surgery (endocystectomy, omentoplasty with or without drainage)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Radical surgery (closed pericystectomy, open pericystectomy, wedge hepatic resection or segmentectomy)
Number of subjects: 32
Study: 14523307

Group type: EXPERIMENTAL
Intervention: CAST (forearm immobilization for 21 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: CONT (dominant arm, no immobilization)
Number of subjects: 6
Study: 10770193

Group type: EXPERIMENTAL
Intervention: 5 microg/kg x day recombinant human GH for 4 days followed by 10 microg/kg x day GH for another 4 days (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 microg/kg x day GH (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 20
Study: 9286529

Group type: EXPERIMENTAL
Intervention: Ambulation at a mean of 2.5 hr after sheath removal (group 1)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Ambulation at a mean of 4.1 hr after sheath removal (group 2)
Number of subjects: 323
Study: 7506161

Group type: EXPERIMENTAL
Intervention: Nimesulide 100mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Nimesulide 200mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Niflumic acid 250mg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 3534005

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 2557364

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Interactional therapy
Number of subjects: 96
Study: 31900486

Group type: EXPERIMENTAL
Intervention: DNA and protein coadministration by needle/syringe
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: DNA administration by Biojector
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: DNA and protein coadministration with DNA given by Biojector
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo by needle/syringe
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo by Biojector
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: DNA prime, protein boost by needle/syringe
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: DNA prime, protein boost with DNA given by Biojector
Number of subjects: 132
Study: 31241441

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy and vitamin D
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antibiotic only
Number of subjects: 60
Study: 29676139

Group type: EXPERIMENTAL
Intervention: Xinling Wan (two pills each time, three times daily for 4 weeks)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Xinling Wan
Number of subjects: 232
Study: 28889258

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 26284748

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 15
Study: 23633698

Group type: EXPERIMENTAL
Intervention: Potassium nitrate dentifrice
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Resin-based composite restoration
Number of subjects: 304
Study: 21165822

Group type: EXPERIMENTAL
Intervention: High-definition endoscopy (HDE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Kudo classification (NBI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vascular pattern intensity (VPI) (NBI)
Number of subjects: 48
Study: 18499587

Group type: EXPERIMENTAL
Intervention: Epiaortic scanning (EAS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (manual aortic palpation without EAS)
Number of subjects: 113
Study: 16556147

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 120

Group type: COMPARATOR
Intervention: Steroid maintenance
Number of subjects: 120
Study: 15284215

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) with a diode laser
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Immunosuppressive/antibiotic treatment (IA)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group (no AH)
Number of subjects: 426
Study: 11331055

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1,380)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo (n = 1,383)
Number of subjects: 2763
Study: 9402552

Group type: EXPERIMENTAL
Intervention: Monte Carlo methods applied to two random samples of 500 values from two populations
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Statistical tests (including Student's t test)
Number of subjects: 100000
Study: 8387637

Group type: EXPERIMENTAL
Intervention: Quadrantectomy followed by radiotherapy
Number of subjects: 567

Group type: COMPARATOR
Intervention: Quadrantectomy without radiotherapy
Number of subjects: 567

Group type: COMPARATOR
Intervention: Quadrantectomy without radiotherapy (age > 55)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 567
Study: 2447789

Group type: EXPERIMENTAL
Intervention: High-protein diet (2 g.kg‐1.day‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-protein diet (0.55 g.kg‐1.day‐1)
Number of subjects: 12
Study: 29902472

Group type: EXPERIMENTAL
Intervention: Home-based moderate-intensity upper-body exercise intervention (n=13)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lifestyle maintenance control group (n=8)
Number of subjects: 21
Study: 27418820

Group type: EXPERIMENTAL
Intervention: IB/SAL-HFA pMDI, 20 μg qid
Number of subjects: 290

Group type: COMPARATOR
Intervention: IB/SAL-CFC pMDI, 20 μg qid
Number of subjects: 290
Study: 26037428

Group type: EXPERIMENTAL
Intervention: Pasireotide 900 μg subcutaneously twice daily for 7 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 22862906

Group type: EXPERIMENTAL
Intervention: Recapture Life intervention (six, weekly, 90-minute online group sessions led by a psychologist)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Peer-support group control (non-directive peer support delivered in an identical manner)
Number of subjects: 90
Study: 20448584

Group type: EXPERIMENTAL
Intervention: Stainless Steel Crown (SSC)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Failed restorations
Number of subjects: 154
Study: 18989993

Group type: EXPERIMENTAL
Intervention: One 800 mg tablet (reference)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two 400 mg tablets (test)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: One 800 mg tablet in fed conditions (test)
Number of subjects: 18

Group type: COMPARATOR
Intervention: One 800 mg tablet in fasting conditions (reference)
Number of subjects: 18
Study: 16433404

Group type: EXPERIMENTAL
Intervention: 14% doxycycline gel (DOXY)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Scaling and root planing with a sonic scaler (SRP)
Number of subjects: 37
Study: 12598265

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of levobupivacaine 0.5%, 3 mL/h (n = 33)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous epidural infusion of levobupivacaine 0.15%, 10 mL/h (n = 27)
Number of subjects: 60
Study: 11079019

Group type: EXPERIMENTAL
Intervention: JPEG compression of raw images
Number of subjects: 0
Study: 9380780

Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Outpatient psychotherapy
Number of subjects: 132
Study: 8295811

Group type: EXPERIMENTAL
Intervention: Clarithromycin oral suspension (7.5 mg/kg, max 500 mg, twice daily)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Cefadroxil oral suspension (15 mg/kg, max 1000 mg, twice daily)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Clarithromycin oral suspension
Number of subjects: 231

Group type: COMPARATOR
Intervention: Cefadroxil oral suspension
Number of subjects: 231
Study: 3552504

Group type: EXPERIMENTAL
Intervention: Oral colonic lavage solution containing sodium sulfate and polyethylene glycol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Whole-gut irrigation using saline via a nasogastric tube
Number of subjects: 34
Study: 31419994

Group type: EXPERIMENTAL
Intervention: AMBER care bundle (intervention)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 65

Group type: COMPARATOR
Intervention: Focus groups with health professionals
Number of subjects: 65
Study: 26232542

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (two doses, 1-month apart)
Number of subjects: 344
Study: 24146363

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT), n = 20, 3 months of vigorous aerobic exercise, supervised three times per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonaerobic (NA), n = 20, no aerobic exercise
Number of subjects: 40